Role of spinal metabotropic glutamate receptor subtype 5 in the development of tolerance to morphine-induced antinociception in rat

Neuroscience Letters

Volumn 420, Issue 2, 2007, Pages 155-159

  Xu, Tao ^a   Jiang, Wei ^a   Du, Dongping ^a   Xu, Yongming ^a   Hu, Qian ^a   Shen, Qin ^b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antinociception; Intrathecal administration; Metabotropic glutamate receptor 5(mGluR5); Morphine; Tolerance

Indexed keywords

2 CHLORO 5 HYDROXYPHENYLGLYCINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CALCIUM ION; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR 5 ANTAGONIST; GLUTAMATE RECEPTOR ANTAGONIST; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; MALE; MORPHINE TOLERANCE; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; CALCIUM; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; GLYCINE; INJECTIONS, SPINAL; MALE; MORPHINE; NEURONS, AFFERENT; NOCICEPTORS; PAIN; PAIN THRESHOLD; PHENYLACETATES; PROTEIN KINASE C; PYRIDINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SPINAL CORD; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 34249320549     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.04.065     Document Type: Article

References (48)

1. Alagarsamy S., Marino M.J., Rouse S.T., Gereau R.W.t., Heinemann S.F., and Conn P.J. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat. Neurosci. 2 (1999) 234-240
2. Allen R.M., and Dykstra L.A. N-methyl-d-aspartate receptor antagonists potentiate the antinociceptive effects of morphine in squirrel monkeys. J. Pharmacol. Exp. Ther. 298 (2001) 288-297
3. Attucci S., Carla V., Mannaioni G., and Moroni F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br. J. Pharmacol. 132 (2001) 799-806
4. Awad H., Hubert G.W., Smith Y., Levey A.I., and Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 20 (2000) 7871-7879
5. Bernardi M., Bertolini A., Szczawinska K., and Genedani S. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Eur. J. Pharmacol. 298 (1996) 51-55
6. Besse D., Lombard M.C., Zajac J.M., Roques B.P., and Besson J.M. Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521 (1990) 15-22
7. Bhargava H.N. Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959, a competitive antagonist of the NMDA receptor. Gen. Pharmacol. 28 (1997) 61-64
8. Bordi F., and Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog. Neurobiol. 59 (1999) 55-79
9. Chen L., and Huang L.Y. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356 (1992) 521-523
10. Crawford J.H., Wainwright A., Heavens R., Pollock J., Martin D.J., Scott R.H., and Seabrook G.R. Mobilisation of intracellular Ca2+ by mGluR5 metabotropic glutamate receptor activation in neonatal rat cultured dorsal root ganglia neurones. Neuropharmacology 39 (2000) 621-630
11. Fan G.H., Zhao J., Wu Y.L., Lou L.G., Zhang Z., Jing Q., Ma L., and Pei G. N-Methyl-d-aspartate attenuates opioid receptor-mediated G protein activation and this process involves protein kinase C. Mol. Pharmacol. 53 (1998) 684-690
12. Fischer B.D., Carrigan K.A., and Dykstra L.A. Effects of N-methyl-d-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice. J. Pain 6 (2005) 425-433
13. Fundytus M.E., and Coderre T.J. Chronic inhibition of intracellular Ca2+ release or protein kinase C activation significantly reduces the development of morphine dependence. Eur. J. Pharmacol. 300 (1996) 173-181
14. Grass S., Hoffmann O., Xu X.J., and Wiesenfeld-Hallin Z. N-methyl-d-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat. Acta Physiol. Scand. 158 (1996) 269-273
15. Gutstein H.B., and Trujillo K.A. MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 626 (1993) 332-334
16. Hoffmann O., and Wiesenfeld-Hallin Z. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats. Neuroreport 7 (1996) 838-840
17. Inturrisi C.E. The role of N-methyl-d-aspartate (NMDA) receptors in pain and morphine tolerance. Minerva Anestesiol. 71 (2005) 401-403
18. Kawabata S., Kohara A., Tsutsumi R., Itahana H., Hayashibe S., Yamaguchi T., and Okada M. Diversity of calcium signaling by metabotropic glutamate receptors. J. Biol. Chem. 273 (1998) 17381-17385
19. Kozela E., Pilc A., and Popik P. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-d-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165 (2003) 245-251
20. Kramer H.K., and Simon E.J. Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: II. Activation and involvement of the alpha, epsilon, and zeta isoforms of PKC. J. Neurochem. 72 (1999) 594-604
21. Li J.Y., Wong C.H., Huang K.S., Liang K.W., Lin M.Y., Tan P.P., and Chen J.C. Morphine tolerance in arthritic rats and serotonergic system. Life Sci. 64 (1999) PL111-PL116
22. Lorrain D.S., Correa L., Anderson J., and Varney M. Activation of spinal group I metabotropic glutamate receptors in rats evokes local glutamate release and spontaneous nociceptive behaviors: effects of 2-methyl-6-(phenylethynyl)-pyridine pretreatment. Neurosci. Lett. 327 (2002) 198-202
23. Ma J., and Pan Z.Z. Contribution of brainstem GABA (A) synaptic transmission to morphine analgesic tolerance. Pain 122 (2006) 163-173
24. Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res. Brain Res. Rev. 30 (1999) 289-304
25. Mao J., Price D.D., Phillips L.L., Lu J., and Mayer D.J. Increases in protein kinase C gamma immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine. Brain Res. 677 (1995) 257-267
26. Mestek A., Hurley J.H., Bye L.S., Campbell A.D., Chen Y., Tian M., Liu J., Schulman H., and Yu L. The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J. Neurosci. 15 (1995) 2396-2406
27. Mills C.D., Xu G.Y., McAdoo D.J., and Hulsebosch C.E. Involvement of metabotropic glutamate receptors in excitatory amino acid and GABA release following spinal cord injury in rat. J. Neurochem. 79 (2001) 835-848
28. Movsesyan V.A., O'Leary D.M., Fan L., Bao W., Mullins P.G., Knoblach S.M., and Faden A.I. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-d-aspartate receptors. J. Pharmacol. Exp. Ther. 296 (2001) 41-47
29. Narita M., Feng Y., Makimura M., Hoskins B., and Ho I.K. A protein kinase inhibitor, H-7, inhibits the development of tolerance to opioid antinociception. Eur. J. Pharmacol. 271 (1994) 543-545
30. Narita M., Suzuki M., Narita M., Niikura K., Nakamura A., Miyatake M., Aoki T., Yajima Y., and Suzuki T. Involvement of spinal metabotropic glutamate receptor 5 in the development of tolerance to morphine-induced antinociception. J. Neurochem. 94 (2005) 1297-1305
31. Narita M., Suzuki M., Narita M., Yajima Y., Suzuki R., Shioda S., and Suzuki T. Neuronal protein kinase C gamma-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine. Eur. J. Neurosci. 19 (2004) 479-484
32. O'Leary D.M., Movsesyan V., Vicini S., and Faden A.I. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131 (2000) 1429-1437
33. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., and Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience 106 (2001) 579-587
34. Quaicoe S., McLaughlin R., and Hassenbusch S. Intrathecal opiate therapy and implantable devices. In: Payne R.P.R., and Stratton Hill C. (Eds). Assessment and Treatment of Cancer Pain vol. 12 (1998), IASP Press, Houston, TX 223-256
35. Salt T.E., and Binns K.E. Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-d-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 100 (2000) 375-380
36. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299 (2001) 12-20
37. Sharif R.N., Osborne M., Coderre T.J., and Fundytus M.E. Attenuation of morphine tolerance after antisense oligonucleotide knock-down of spinal mGluR1. Br. J. Pharmacol. 136 (2002) 865-872
38. Smith F.L., Smith P.A., Dewey W.L., and Javed R.R. Effects of mGlu1 and mGlu5 metabotropic glutamate antagonists to reverse morphine tolerance in mice. Eur. J. Pharmacol. 492 (2004) 137-142
39. Storkson R.V., Kjorsvik A., Tjolsen A., and Hole K. Lumbar catheterization of the spinal subarachnoid space in the rat. J. Neurosci. Methods 65 (1996) 167-172
40. Thomas L.S., Jane D.E., Gasparini F., and Croucher M.J. Glutamate release inhibiting properties of the novel mGlu (5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 41 (2001) 523-527
41. Thomas L.S., Jane D.E., Harris J.R., and Croucher M.J. Metabotropic glutamate autoreceptors of the mGlu (5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology 39 (2000) 1554-1566
42. Trujillo K.A., and Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251 (1991) 85-87
43. Ugolini A., Corsi M., and Bordi F. Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 38 (1999) 1569-1576
44. Wang Z., Arden J., and Sadee W. Basal phosphorylation of mu opioid receptor is agonist modulated and Ca2+-dependent. FEBS Lett. 387 (1996) 53-57
45. Welch S.P., and Bass P.P. Modulation of free intracellular calcium levels [(Ca++)i] in brain and spinal cord of morphine-tolerant rats and mice. Pharmacol. Biochem. Behav. 51 (1995) 57-63
46. Wong C.S., Chang Y.C., Yeh C.C., Huang G.S., and Cherng C.H. Loss of intrathecal morphine analgesia in terminal cancer patients is associated with high levels of excitatory amino acids in the CSF. Can. J. Anaesth. 49 (2002) 561-565
47. Wu Z.Q., Chen J., Chi Z.Q., and Liu J.G. Involvement of dopamine system in regulation of Na+,K+-ATPase in the striatum upon activation of opioid receptors by morphine. Mol. Pharmacol. 71 (2007) 519-530
48. Xie W., Samoriski G.M., McLaughlin J.P., Romoser V.A., Smrcka A., Hinkle P.M., Bidlack J.M., Gross R.A., Jiang H., and Wu D. Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10385-10390